Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02491359 · ClinicalTrials.gov registry record · Phase 2

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
5
Study locations

NCT02491359 is a Phase 2 study of Chronic Graft Versus Host Disease that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 20 participants, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02491359, a Phase 2 study of Chronic Graft Versus Host Disease, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
5
Study locations

Study Summary

This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually occurring more than three months after transplant, in which donor cells damage the host tissue. Carfilzomib may be an effective treatment for chronic graft-versus-host disease.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Laboratory Biomarker Analysis
  • OTHER Questionnaire Administration
  • DRUG Carfilzomib

Study Locations (5)

Florida

  • Moffitt Cancer Center - Tampa

New York

  • Roswell Park Cancer Institute - Buffalo

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Pennsylvania

  • University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-11-12
Est. Completion 2018-09-12
Phase Phase 2

Sponsor

Fred Hutchinson Cancer Center

483 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02491359

The ClinicalTrials.gov registry entry for NCT02491359 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (83% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT02491359 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT02491359 about?

NCT02491359 is a clinical study titled "Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease". This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually occurring more than three months after transplant, in which donor cel...

What is the current status of trial NCT02491359?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-11-12. Estimated completion is 2018-09-12.

What conditions does trial NCT02491359 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT02491359?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Carfilzomib (DRUG).

Who is sponsoring clinical trial NCT02491359?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02491359 being conducted?

This trial has 5 study locations across Florida, New York, Ohio, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Graft Versus Host Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.